EspeRare and Pierre Fabre begin Edelife, a phase II clinical trial for XLHED, with site in Germany. Purpose is to confirm Dr. Holm Schneider’s findings from treating three babies prenatally with ER-004 who are now sweating normally and have other improved symptoms.
